Orforglipron vs Wegovy Pill — The First Two Oral GLP-1s for Obesity

What Is Foundayo (Orforglipron)?

Foundayo is the brand name for orforglipron, Eli Lilly’s oral, once-daily GLP-1 receptor agonist for obesity. It is the first non-peptide small-molecule GLP-1 in pill form to reach the U.S. market. The compound (LY3502970) originated as a Chugai discovery and was licensed by Lilly in 2018.

The FDA approved Foundayo on April 1, 2026 — 50 days from filing — under the agency’s first-ever Commissioner’s National Priority Voucher pilot. That made it the fastest approval of a new molecular entity since 2002. The approved indication is chronic weight management in adults with obesity, or overweight with at least one weight-related comorbidity, alongside reduced-calorie diet and increased physical activity.

The pivotal ATTAIN-1 trial (NEJM, November 2025; n=3,127, 72 weeks) showed mean weight loss of 11.2% at the 36 mg dose versus 2.1% on placebo, with 54.6% of participants losing at least 10% of body weight and 18.4% losing at least 20%. ATTAIN-2 (n=1,646, 72 weeks) tested orforglipron in adults with obesity plus type 2 diabetes — 36 mg produced 10.5% weight loss and a 1.8 percentage-point A1C reduction.

Mechanistically, orforglipron is a non-peptide small-molecule GLP-1 receptor agonist. It binds and activates the GLP-1 receptor without being a peptide. That has two direct consequences: it is absorbed without the SNAC permeation enhancer that peptide-based oral semaglutide requires, and it scales on small-molecule manufacturing rather than peptide synthesis. For a deeper look at the mechanism and pipeline history, see our orforglipron profile and the Foundayo FDA approval breakdown.

What Is the Wegovy Pill?

The Wegovy pill is the brand name for Novo Nordisk’s oral semaglutide 25 mg for chronic weight management. It is the same molecule used in Ozempic and the Wegovy injection, but reformulated with the absorption enhancer SNAC (sodium N-(8-[2-hydroxybenzoyl]amino)-caprylate) so it can be taken as a tablet. It was FDA-approved on December 22, 2025 — the first oral GLP-1 receptor agonist approved for obesity.

Unlike the existing oral-semaglutide diabetes product (Rybelsus, max 14 mg), the Wegovy pill is a higher-dose 25 mg tablet specifically for weight management. It is also approved for reducing the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) in adults with obesity or overweight plus established cardiovascular disease — an indication orforglipron does not yet carry.

The pivotal OASIS-4 trial (NEJM, September 2025; n=307, 71 weeks) showed mean weight change of −13.6% at 64 weeks under the treatment-policy estimand and −16.6% in adherent participants, versus −2.2% with placebo. Among adherent participants, 34.4% achieved at least 20% weight loss versus 2.9% with placebo.

Because oral semaglutide is a peptide, it has to clear a structural problem: peptides degrade in the stomach and absorb poorly. Novo’s solution is SNAC, which transiently enhances gastric absorption — but only when there is no food, drink, or competing molecules in the stomach. That is why the dosing instructions are specific, and why adherence to the fasting window directly determines absorption.

Efficacy: Weight Loss Side by Side

Cross-trial efficacy in obesity numerically favors the Wegovy pill, but the comparison comes with two caveats: different trial designs and durations, and no direct head-to-head at obesity doses.

The First Direct Comparison — ACHIEVE-3

The only direct head-to-head trial between the two drugs is ACHIEVE-3, published in The Lancet on February 26, 2026. It enrolled 1,698 adults with type 2 diabetes inadequately controlled on metformin and randomized them across four arms: orforglipron 12 mg, orforglipron 36 mg, oral semaglutide 7 mg, and oral semaglutide 14 mg, over 52 weeks.

Orforglipron 36 mg was superior to oral semaglutide 14 mg on every primary and key secondary endpoint: A1C reduction of 2.2 percentage points versus 1.4, and weight loss of 9.2% (19.7 lb) versus 5.3% (11.0 lb) — 73.6% greater relative weight loss. 85.4% of participants on orforglipron 36 mg reached A1C below 7%, versus 66.1% on oral semaglutide 14 mg.

The crucial caveat: ACHIEVE-3 used the 14 mg type 2 diabetes dose of oral semaglutide, not the 25 mg obesity dose that is sold as the Wegovy pill. The trial established orforglipron’s superiority over oral semaglutide in diabetes at the lower, T2D-approved doses, but it does not establish that orforglipron beats the Wegovy pill for weight loss in obesity. Researchers extrapolating across formulations and indications need to keep that scope explicit.

For the broader 2026 oral landscape — including triple agonists like retatrutide and dual amylin/GLP-1 candidates — see our oral obesity drugs 2026 overview and best obesity drug 2026 comparison.

Dosing and Daily Use

This is where the practical gap is largest. Daily friction is often the single biggest determinant of long-term adherence in oral therapies — and on this axis the two drugs are not equivalent.

Foundayo (orforglipron)

Once-daily tablet. Dosing starts at 0.8 mg and titrates over months — 2.5 mg, 5.5 mg, 9 mg, 14.5 mg — up to a 17.2 mg maintenance dose. It can be taken at any time of day, with or without food, with normal water intake. That is a direct consequence of the small-molecule chemistry: it does not depend on a permeation enhancer.

Wegovy pill (oral semaglutide 25 mg)

Once-daily, but the dosing instructions are constrained:

• Take first thing in the morning.
• On an empty stomach, with no more than 4 oz (120 mL) of plain water.
• Wait at least 30 minutes before food, other beverages, or other oral medications.

This protocol exists because SNAC’s absorption-enhancing effect is transient and competes with anything else in the stomach. Skipping the fast or drinking too much water reduces semaglutide absorption — in clinical practice, missed or improperly taken doses translate into less weight loss. For researchers comparing real-world effectiveness, that practical asymmetry should be weighed alongside the headline efficacy numbers.

Safety and Tolerability

Both drugs share the GLP-1 class side-effect profile: gastrointestinal events — nausea, vomiting, diarrhea, constipation — are the most common adverse events, generally dose-dependent and most pronounced during titration.

Orforglipron (ATTAIN-1): treatment discontinuation due to adverse events ranged from 5.3% to 10.3% across orforglipron groups versus 2.1–2.7% on placebo. At the 36 mg dose, nausea reached 36.4%, diarrhea 27%, vomiting 23%.

Oral semaglutide 25 mg (OASIS-4): GI adverse events were reported in 74.0% of participants on oral semaglutide versus 42.2% on placebo. A notable finding: serious adverse events were lower with oral semaglutide (3.9%) than with placebo (8.8%) — an unusual signal that the trial investigators flagged in the publication.

Both carry a boxed warning for thyroid C-cell tumors / medullary thyroid carcinoma. That is the standard GLP-1 class warning and not a differentiator between the two. For tolerability nuance across the broader GLP-1 family, see our Ozempic vs Mounjaro vs Wegovy side effects comparison and the data on GLP-1 side-effect patterns reported in online communities.

In the UAE, the situation is asymmetric. The Emirates Drug Establishment approved Foundayo on April 3, 2026, with patient availability beginning May 2026. The Wegovy pill is not yet approved by EDE or MoHAP as of May 1, 2026 — so for UAE researchers cross-referencing local availability, only Foundayo is currently in-market. For the broader UAE GLP-1 landscape including injectable Ozempic, Mounjaro, Wegovy, and Saxenda pricing, see our GLP-1 medications UAE availability and cost guide. For the latest tracker of approval status across regulators, see is orforglipron approved and the obesity drug approval tracker 2026.

Bottom Line — Where Each Drug Fits

For a researcher cataloguing the 2026 oral GLP-1 race, the two drugs differentiate on three axes:

1. Numerical efficacy in obesity (cross-trial only). The Wegovy pill 25 mg is ahead on absolute weight loss (−13.6% vs −11.2%); orforglipron has not been tested directly against it at obesity doses. Direct head-to-head obesity data may emerge in future trials, but it does not exist today.

2. Daily practicality. Foundayo’s any-time, no-fasting profile is a meaningful real-world advantage. Whether that closes the headline efficacy gap in actual use is an empirical question — clinical-trial efficacy and real-world effectiveness diverge most when daily-use friction is high.

3. Indication breadth. The Wegovy pill carries a MACE-reduction indication that orforglipron does not. Orforglipron’s diabetes filing is expected later in 2026, which would close part of that gap.

The pipeline behind both drugs is moving fast. Triple agonists like retatrutide are showing higher Phase 2 weight-loss numbers than either of these orals, and dual amylin/GLP-1 candidates are working through Phase 3. For a three-way comparison of the leading injectables, see our retatrutide vs tirzepatide vs CagriSema analysis. For the latest dual-agonist injectable head-to-head, see our CagriSema vs tirzepatide REDEFINE 4 breakdown. For the commercial framing of Foundayo’s approval, label, and pricing, see Foundayo (orforglipron) FDA approved.